Document detail

The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.

Treatment,  TB,  TB drugs,  Guidelines,  drug-resistant TB,  MDR-TB,  Multi-drugresistant Tuberculosis/MDR-TB,